CHARLES RIVER LABORATORIES INTERNATIONAL, INC. acquired PathoQuest SAS for EUR 51.6 million (approximately $60.0 million), a transaction announced in January 2026, structured as option exercise for remaining ~79% equity interest (cash and Credit Facility proceeds).
PathoQuest SAS operates in Manufacturing. Provider of next-generation-sequencing-based biosafety and viral testing services; Charles River exercised its option to acquire the remaining approximately 79% equity interest.
Strengthens Charles River's biologics testing and biosafety capabilities within its Manufacturing segment.
Advisory firms were not disclosed for this transaction.